Mitumomab

Mitumomab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	GD3 ganglioside
Identifiers
CAS Number	216503-58-1
ATC code	none

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009^[update], the drug is undergoing Phase III clinical trials.^[1]^[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

v t e Mouse monoclonal antibodies ("-o-")
"-govo-" (ovarian tumor)	Abagovomab, Igovomab, Oregovomab
"-limo-" (immune system)	Afelimomab, Elsilimomab, Faralimomab, Gavilimomab, Inolimomab, Maslimomab, Nerelimomab, Odulimomab, Telimomab aritox, Vepalimomab, Zolimomab aritox
"-tumo-" (miscellaneous tumor)	Altumomab pentetate, Anatumomab mafenatox, Arcitumomab, Bectumomab, Blinatumomab, CC49, Detumomab, Ibritumomab tiuxetan, Minretumomab, Mitumomab, Naptumomab estafenatox, Nofetumomab merpentan, Pemtumomab, Pintumomab, Satumomab pendetide, Taplitumomab paptox, Tenatumomab, Tositumomab, 3F8
"-leso-" (infectious lesions)	Besilesomab, Fanolesomab^§, Lemalesomab, Sulesomab
"-ciro-" (cardiovascular)	Biciromab^§, Imciromab^§
"-pro-" (prostate tumor)	Capromab pendetide
"-baco-" (bacterial)	Edobacomab
"-colo-" (colonic tumor)	Edrecolomab, Nacolomab tafenatox
^§Withdrawn